Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBIT Margin (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIT Margin for 5 consecutive years, with 268.12% as the latest value for Q1 2020.

  • On a quarterly basis, EBIT Margin rose 18772368.0% to 268.12% in Q1 2020 year-over-year; TTM through Dec 2020 was 6121.96%, a 11678082.0% decrease, with the full-year FY2019 number at 11288.89%, down 1103466.0% from a year prior.
  • EBIT Margin was 268.12% for Q1 2020 at Forte Biosciences, down from 519388.89% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 519388.89% in Q4 2019 to a low of 212311.11% in Q4 2018.
  • A 5-year average of 14708.76% and a median of 7.92% in 2018 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -14414705bps in 2018, then surged 73170000bps in 2019.
  • Forte Biosciences' EBIT Margin stood at 777.85% in 2016, then plummeted by -13839bps to 106870.0% in 2017, then plummeted by -99bps to 212311.11% in 2018, then skyrocketed by 345bps to 519388.89% in 2019, then tumbled by -100bps to 268.12% in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBIT Margin are 268.12% (Q1 2020), 519388.89% (Q4 2019), and 7600.0% (Q3 2019).